Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

2.

Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.

Wang W, Chen Q, Ford-Siltz LA, Katzelnick LC, Parra GI, Song HS, Vassell R, Weiss CD.

Clin Infect Dis. 2019 May 30;68(12):2067-2078. doi: 10.1093/cid/ciy818.

PMID:
30256912
3.

Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.

Virnik K, Nesti E, Dail C, Scanlan A, Medvedev A, Vassell R, McGuire AT, Stamatatos L, Berkower I.

Vaccine. 2018 Aug 16;36(34):5166-5172. doi: 10.1016/j.vaccine.2018.07.010. Epub 2018 Jul 20.

PMID:
30037665
4.

HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.

Keller PW, Morrison O, Vassell R, Weiss CD.

J Virol. 2018 Jul 31;92(16). pii: e00583-18. doi: 10.1128/JVI.00583-18. Print 2018 Aug 15.

5.

Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.

Wang W, Song HS, Keller PW, Alvarado-Facundo E, Vassell R, Weiss CD.

J Virol. 2018 May 29;92(12). pii: e00247-18. doi: 10.1128/JVI.00247-18. Print 2018 Jun 15.

6.

Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.

Alvarado-Facundo E, Vassell R, Schmeisser F, Weir JP, Weiss CD, Wang W.

PLoS One. 2016 Feb 10;11(2):e0149149. doi: 10.1371/journal.pone.0149149. eCollection 2016.

7.

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity.

Wang W, DeFeo CJ, Alvarado-Facundo E, Vassell R, Weiss CD.

J Virol. 2015 Oct;89(20):10602-11. doi: 10.1128/JVI.00939-15. Epub 2015 Aug 12.

8.

Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses.

Wang W, Alvarado-Facundo E, Chen Q, Anderson CM, Scott D, Vassell R, Weiss CD.

J Infect Dis. 2016 Feb 1;213(3):403-6. doi: 10.1093/infdis/jiv407. Epub 2015 Aug 4.

PMID:
26243315
9.

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, Montefiori DC, Barnett SW, Weiss CD.

PLoS One. 2015 Jun 18;10(6):e0128562. doi: 10.1371/journal.pone.0128562. eCollection 2015.

10.

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.

De Feo CJ, Wang W, Hsieh ML, Zhuang M, Vassell R, Weiss CD.

Retrovirology. 2014 Oct 2;11:86. doi: 10.1186/s12977-014-0086-8.

11.

Clinical impact of biopsy method on the quality of surgical management in melanoma.

Kaiser S, Vassell R, Pinckney RG, Holmes TE, James TA.

J Surg Oncol. 2014 Jun;109(8):775-9. doi: 10.1002/jso.23580. Epub 2014 Feb 21.

PMID:
24862925
12.

Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD.

J Biol Chem. 2012 Mar 9;287(11):8297-309. doi: 10.1074/jbc.M111.324483. Epub 2012 Jan 10.

14.

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2.

Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, Xie H, Ye Z, Scott D, Weiss CD.

PLoS Pathog. 2011 Jun;7(6):e1002081. doi: 10.1371/journal.ppat.1002081. Epub 2011 Jun 9.

15.

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.

Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD.

Virology. 2010 Nov 25;407(2):374-80. doi: 10.1016/j.virol.2010.08.027. Epub 2010 Sep 24.

16.

Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.

Wang W, Xie H, Ye Z, Vassell R, Weiss CD.

J Virol Methods. 2010 May;165(2):305-10. doi: 10.1016/j.jviromet.2010.02.009. Epub 2010 Feb 11.

PMID:
20153374
17.

Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.

Vaccine. 2010 Jan 8;28(3):699-706. doi: 10.1016/j.vaccine.2009.10.078. Epub 2009 Nov 1.

PMID:
19887133
18.

Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.

Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K.

Biochem Pharmacol. 2009 Nov 15;78(10):1298-304. doi: 10.1016/j.bcp.2009.06.104. Epub 2009 Jul 2.

PMID:
19576865
19.

Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.

Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD.

J Virol Methods. 2008 Nov;153(2):111-9. doi: 10.1016/j.jviromet.2008.07.015. Epub 2008 Sep 4.

PMID:
18722473
20.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325
21.

Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD.

J Virol. 2005 Apr;79(8):4774-81.

23.

Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.

He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD.

J Virol. 2003 Feb;77(3):1666-71.

25.

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

Scharton-Kersten T, Yu Jm, Vassell R, O'Hagan D, Alving CR, Glenn GM.

Infect Immun. 2000 Sep;68(9):5306-13.

26.

Principles of transcutaneous immunization using cholera toxin as an adjuvant.

Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, Alving CR.

Vaccine. 1999 Oct 1;17 Suppl 2:S37-43.

PMID:
10506407
27.

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants.

Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR.

Infect Immun. 1999 Mar;67(3):1100-6.

28.

Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR.

J Immunol. 1998 Oct 1;161(7):3211-4.

29.

Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus).

Asher LV, Binn LN, Mensing TL, Marchwicki RH, Vassell RA, Young GD.

J Med Virol. 1995 Nov;47(3):260-8.

PMID:
8551278
30.

Cell-mediated immunity in owl monkeys following inoculation with hepatitis A virus.

Asher LV, Vassell RA, Binn LN, Polotsky YE.

Adv Exp Med Biol. 1995;371B:1591-3. No abstract available.

PMID:
7502862
31.

Immunohistochemical detection of cytokines in tissues of Aotus monkeys infected with hepatitis A virus.

Polotsky YE, Vassell RA, Binn LN, Asher LV.

Ann N Y Acad Sci. 1994 Aug 15;730:318-21.

PMID:
8080199

Supplemental Content

Loading ...
Support Center